Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about Phase 2 Trial
Recent news which mentions Phase 2 Trial
< Previous
1
2
3
4
5
6
7
8
9
Next >
ALX Oncology's Evorpacept Data Fails To Impress At ASH Presentation
December 13, 2021
Tickers
ALXO
Tags
Biotech
ALXO
Market News
From
Benzinga
Viracta Therapeutics Posts Data From Lymphoma Trial At ASH Presentation
December 13, 2021
Tickers
VIRX
Tags
Movers
Phase 2 Trial
Trading Ideas
From
Benzinga
Harpoon Shares Jump After Early Data From BCMA-Targeting Myeloma Candidate At ASH Meet
December 13, 2021
Tickers
HARP
Tags
Biotech
multiple myeloma
Market News
From
Benzinga
JNJ's Janssen Posts Two Years Survival Data On BCMA Cell Therapy In Multiple Myeloma
December 13, 2021
Tickers
JNJ
LEGN
Tags
Briefs
Health Care
Biotech
From
Benzinga
Jazz Posts New Data for ALL/LBL Treatment At ASH 2021 Annual Meeting
December 13, 2021
Tickers
JAZZ
Tags
Phase 2 Trial
Phase 3 Trial
Briefs
From
Benzinga
Roche Uncorks Favorable Responses From Mosunetuzumab In Follicular Lymphoma Settings
December 13, 2021
Tickers
RHHBF
RHHBY
RHHVF
Tags
RHHVF
Benzinga
Phase 2 Trial
From
Benzinga
Bluebird Bio Posts Updated Data From Sickle Cell Gene Therapy Program
December 13, 2021
Tickers
BLUE
Tags
Small Cap
Benzinga
Health Care
From
Benzinga
Merus Shares Updated Data From Zeno Triplet Combo Data In Breast Cancer Settings
December 10, 2021
Tickers
MRUS
Tags
Biotech
News
Market News
From
Benzinga
Infinity Pharma Shares Updated Eganelisib Combo Therapy In Breast Cancer Trial
December 10, 2021
Tickers
BMY
INFI
RHHBF
RHHBY
Tags
Benzinga
breast cancer
RHHVF
From
Benzinga
Moderna Posts Data From Early mRNA Flu Vaccine Study, Pivotal Trial On Its Way
December 10, 2021
Tickers
BNTX
MRNA
SNY
Tags
News
why it's moving
Phase 1 Trial
From
Benzinga
Roche Posts Encouraging Follow-up Data From Tiragolumab/Tecentriq Trial In Lung Cancer
December 10, 2021
Tickers
RHHBF
RHHBY
RHHVF
Tags
General
RHHBF
Market News
From
Benzinga
Angion's ANG-3777 Faces Third Failure In 2021, This Time Flunks Acute Kidney Injury Trial
December 10, 2021
Tickers
ANGN
Tags
Benzinga
Short Ideas
Briefs
From
Benzinga
Innate Pharma Says Chemo-Free Monalizumab Triplet Therapy Shows Preliminary Anti-Cancer Activity
December 09, 2021
Tickers
AZN
AZNCF
IPHA
Tags
Trading Ideas
Health Care
Phase 2 Trial
From
Benzinga
Johnson & Johnson Posts Additional RSV Vaccine Data
December 07, 2021
Tickers
JNJ
Tags
JNJ
General
Benzinga
From
Benzinga
Ideaya Reports New Data From Combo Therapy Regime In Pretreated Eye Cancer Patients
December 07, 2021
Tickers
IDYA
Tags
Biotech
Health Care
Briefs
From
Benzinga
Prometheus Biosciences Posts Phase 1 Data On Lead Therapeutic Candidate
December 07, 2021
Tickers
RXDX
Tags
Briefs
Health Care
Trading Ideas
From
Benzinga
Bellicum Secures $35M Via Equity Funding, Posts Interim Data From Early GoCAR-T Cancer Studies
December 06, 2021
Tickers
BLCM
Tags
Benzinga
Financing
BLCM
From
Benzinga
Ocular Therapeutix's Dexamethasone Ophthalmic Insert Meets Primary Goal In Dry Eye Disease Trial
December 06, 2021
Tickers
OCUL
Tags
Health Care
Trading Ideas
Briefs
From
Benzinga
GH Research Posts Data From Treatment-Resistant Depression Trial
December 06, 2021
Tickers
GHRS
Tags
Briefs
GHRS
Biotech
From
Benzinga
Bolt Biotherapeutics Reveals Early Data From BDC-1001 Immuno-Oncology Candidate
December 06, 2021
Tickers
BOLT
Tags
BOLT
Biotech
General
From
Benzinga
Molecular Partners' Ensovibep Shows Early Safety Profile In COVID-19
December 06, 2021
Tickers
MOLN
Tags
Small Cap
General
Benzinga
From
Benzinga
Stoke Touts Early Signs Of Efficacy For Antisense Drug In Dravet Syndrome
December 03, 2021
Tickers
STOK
Tags
Small Cap
Benzinga
Movers
From
Benzinga
Kazia Unveils Final Data From Mid-Stage Paxalisib Data In Newly Diagnosed Glioblastoma Patients
December 03, 2021
Tickers
KZIA
Tags
Brain Tumor
Benzinga
Movers
From
Benzinga
Xenon Stock Jumps On New Encouraging Data From Epilepsy Treatment
December 03, 2021
Tickers
XENE
Tags
News
Market News
General
From
Benzinga
SQZ Biotechnologies' Cell Therapy Shows Favorable Safety Profile In HPV+ Solid Tumors
December 02, 2021
Tickers
SQZ
Tags
Phase 2 Trial
Movers
Briefs
From
Benzinga
ARCA Biopharma Expects Data Readout From Mid-Stage COVID-19 Trial In Q1 2022
December 02, 2021
Tickers
ABIO
Tags
General
Benzinga
News
From
Benzinga
FDA Signs Off Chemomab's Lead Candidate Mid-Stage Study In Bile Duct Disease
December 02, 2021
Tickers
CMMB
Tags
Benzinga
Briefs
Health Care
From
Benzinga
VBI Vaccines Reveals Updated Overall Survival Data From Brain Cancer Vaccine Trial
December 02, 2021
Tickers
GSK
VBIV
Tags
brain cancer
Briefs
Health Care
From
Benzinga
Inhibrx Precision Cancer Antibody Receives FDA Orphan Drug Tag For Rare Bone Cancer
December 02, 2021
Tickers
INBX
Tags
News
Phase 1 Trial
Market News
From
Benzinga
Clene's Amyotrophic Lateral Sclerosis Candidate Shows Favorable Impact On Disease Progression
December 01, 2021
Tickers
CLNN
Tags
Briefs
Health Care
Trading Ideas
From
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.